CDER Ad Division To Create Separate Biologics Review Group
Executive Summary
FDA's drug advertising division will establish a separate team to oversee the review of ads for biologics as part of the CBER/CDER consolidation, Division of Drug Marketing, Advertising & Communications Director Tom Abrams said at the Drug Information Association annual meeting in San Antonio June 17
You may also be interested in...
Botox Cosmetic Warning Letter: FDA Frowns On Broad Claims, Wants Correction
FDA is asking Allergan to correct information in its Botox Cosmetic DTC print campaign regarding the scope of the product's indication
Botox Cosmetic Warning Letter: FDA Frowns On Broad Claims, Wants Correction
FDA is asking Allergan to correct information in its Botox Cosmetic DTC print campaign regarding the scope of the product's indication
CBER/CDER Consolidation: Weiss Named Acting Director Of New ODE VI
CBER Office of Therapeutics Research & Review Acting Director Sharon Risso will continue to serve as the point person for biologics staff transition questions after the consolidation with FDA's drugs center